Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

BACKGROUND: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). METHODS: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Paul W, Rennard, Stephen I, Agusti, Alvar, Chanez, Pascal, Magnussen, Helgo, Fabbri, Leonardo, Donohue, James F, Bateman, Eric D, Gross, Nicholas J, Lamarca, Rosa, Caracta, Cynthia, Gil, Esther Garcia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098801/
https://www.ncbi.nlm.nih.gov/pubmed/21518460
http://dx.doi.org/10.1186/1465-9921-12-55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098801/
https://www.ncbi.nlm.nih.gov/pubmed/21518460
http://dx.doi.org/10.1186/1465-9921-12-55

Ejemplares similares